Search

Search Constraints

You searched for: Author/Creator Repetto, Enrico

Search Results

1. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2. Issue 11 (20th August 2020)

2. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Issue 10 (October 2020)

4. Hormone‐substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active‐controlled DURATION‐8 study. Issue 1 (8th October 2019)